Equillium, Inc. (EQ)
| Market Cap | 90.36M +13.4% |
| Revenue (ttm) | n/a |
| Net Income | -18.01M |
| EPS | -0.20 |
| Shares Out | 63.41M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 126,617 |
| Open | 1.500 |
| Previous Close | 1.500 |
| Day's Range | 1.425 - 1.500 |
| 52-Week Range | 0.756 - 3.540 |
| Beta | 1.92 |
| Analysts | Strong Buy |
| Price Target | 8.56 (+500.7%) |
| Est. Earnings | Nov 12, 2026 |
About EQ
Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases. It also develops EQ302, a bi-specific inhibitor of IL-15 and IL-21 formulated for oral delivery for the treatment of celiac diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its n... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for EQ stock is "Strong Buy." The 12-month stock price target is $8.56, which is an increase of 500.70% from the latest price.
News
Equillium assumed with an Outperform at Leerink
Leerink assumed coverage of Equillium (EQ) with an Outperform rating and $6 price target The firm notes Equillium trades at an undemanding valuation for a novel oral mechanism in IBD,…
Equillium Announces Poster Presentation at the 50th Anniversary La Jolla Immunology Conference
New preclinical data further characterizes EQ504's coordinated effects across epithelial and immune compartments in intestinal inflammation New preclinical data further characterizes EQ504's coordinat...
Equillium receives HREC clearance for EQ504 in Australia
Equillium (EQ) announced that the company has received Human Research Ethics Committee, or HREC, approval and clearance from the Therapeutic Goods Administration, or TGA, in Australia under the Clinic...
Equillium Receives Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of EQ504
On track to initiate dosing by early November 2026; topline Phase 1 proof-of-mechanism data anticipated approximately six months following study initiation
Equillium Announces Poster Presentations at the 7th International AHR Conference
New preclinical data further characterize EQ504's effects on epithelial barrier repair and immune regulation New preclinical data further characterize EQ504's effects on epithelial barrier repair and ...
Equillium Transcript: Stifel 2026 Virtual Immunology and Inflammation Forum
EQ504, a novel oral AhR modulator, is advancing to phase I for ulcerative colitis with strong preclinical and translational support, while an inhaled version targets lung diseases. EQ302, an oral peptide for celiac disease, is also progressing. Financing is secured for near-term milestones.
Equillium to Participate in Stifel's 2026 Virtual Immunology and Inflammation Forum
LA JOLLA, Calif., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today ann...
Equillium Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
EQ504, a potent and selective AhR modulator, is advancing into clinical trials for UC with a colon-targeted formulation and plans for lung indications using inhaled delivery. The program is well-funded, differentiated by its design and delivery, and supported by robust preclinical safety and mechanistic data.
Equillium management to meet with Piper Sandler
Meeting to be held on September 8 hosted by Piper Sandler.
Equillium to Participate in Upcoming Investor Conferences
LA JOLLA, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today ann...
Equillium reports Q2 EPS (4c), consensus (6c)
“We continue to make meaningful progress advancing EQ504 toward the clinic,” said Bruce Steel, Chief Executive Officer of Equillium (EQ). “Our colon-targeted formulated product has been manufactured, ...
Equillium Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
Phase 1 proof-of-mechanism study of EQ504 initiation expected in Q4 2026, with data expected approximately six months thereafter Cash and cash equivalents of $57.2 million expected to fund operations ...
Equillium Earnings release: Q2 2026
Equillium released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
Equillium Quarterly report: Q2 2026
Equillium has published its Q2 2026 quarterly earnings report on August 13, 2026.
Equillium Slides: Corporate presentation
Equillium has posted slides in relation to its latest quarterly earnings report, which was published on August 13, 2026.
Equillium initiated with a Buy at Clear Street
Clear Street analyst Kaveri Pohlman initiated coverage of Equillium (EQ) with a Buy rating and $9 price target The company’s lead asset EQ504 offers an attractive risk/reward profile in inflammatory…
Equillium initiated with an Overweight at Piper Sandler
Piper Sandler analyst Yasmeen Rahimi initiated coverage of Equillium (EQ) with an Overweight rating and $20 price target The firm views the shares as “significantly undervalued” relative to competitor...
EQ Works Expands Multi-Year Partnership with Leading Canadian Publisher to Include SaaS License for ClearLake
Three-year renewal follows early campaign results that delivered up to 40% increases in average order value and nearly double the conversion rates using ClearLake TORONTO, ON / ACCESS Newswire / June ...
Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
LA JOLLA, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today anno...
Equillium to Participate in the 2026 Jefferies Global Healthcare Conference
LA JOLLA, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today annou...
Equillium price target raised to $7 from $6 at Raymond James
Raymond James raised the firm’s price target on Equillium (EQ) to $7 from $6 and keeps a Strong Buy rating on the shares. Equillium’s EQ504 is a selective AhR activator…
Leerink upgrades Equillium on ‘supportive’ ulcerative colitis data
Leerink upgraded Equillium (EQ) to Outperform from Market Perform with a price target of $6, up from $1. The firm cites growing clinical and mechanistic validation for aryl hydrocarbon receptor…
Equillium upgraded to Outperform from Market Perform at Leerink
Leerink upgraded Equillium (EQ) to Outperform from Market Perform with a $6 price target
Equillium Transcript: Status update
EQ504 and ABX464 are confirmed AhR modulators that induce miR-124 and anti-inflammatory cytokines in immune cells, improving barrier function and reducing inflammation. EQ504 is designed for high colon tissue exposure and will enter phase I trials mid-year, with CYP1A1 as a key biomarker.
Equillium Slides: Status update
Equillium has posted slides in relation to its latest quarterly earnings report, which was published on May 27, 2026.